Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review

doi:10.12998/wjcc.v14.i12.119171

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 12

This Article

(34)

(43)

(0)

(1426)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. Apr 26, 2026; 14(12): 119171
Published online Apr 26, 2026. doi: 10.12998/wjcc.v14.i12.119171

Table 6 Summary of safety outcomes from newly included studies

Ref.	Total patients	Follow-up duration	Any AE (%)	Serious AE (%)	Discontinuation due to AE (%)	Most common AEs
Warren et al[2], 2025 (ADvantage)	237 (lebrikizumab arm)	16 weeks	42.6	2.5	3.4	Injection site reactions, nasopharyngitis
Guttman-Yassky et al[1], 2025 (ADjoin)	463	104 weeks	78.4	4.8	5.2	Nasopharyngitis, injection site reactions, conjunctivitis
Tanaka et al[3], 2024	156	52 weeks	Not reported	Not reported	4.5	Nasopharyngitis, injection site reactions
Avallone et al[4], 2025 (Italy RWE)	394	16-24 weeks	18.3	1.5	8.1	Injection site reactions (6.9%), URTI (4.6%)
Abraheem et al[5], 2025 (United Kingdom RWE)	128	16 weeks	15.6	0.8	6.3	Injection site reactions, conjunctivitis
Hagino et al[6], 2025 (Japan RWE)	938	24 weeks	12.8	1.2	4.9	Nasopharyngitis, injection site reactions

AE: Adverse event; RWE: Real-world evidence; URTI: Upper respiratory tract infection.

Full Size Table

Citation: Alphonse C, Irfan M, Céspedes SCT, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Mendoza LAG, Sardar A, Diaz AM, Jawed I. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World J Clin Cases 2026; 14(12): 119171
URL: https://www.wjgnet.com/2307-8960/full/v14/i12/119171.htm
DOI: https://dx.doi.org/10.12998/wjcc.v14.i12.119171

Alphonse C, Irfan M, Céspedes SCT, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Mendoza LAG, Sardar A, Diaz AM, Jawed I. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World J Clin Cases 2026; 14(12): 119171 [DOI: 10.12998/wjcc.v14.i12.119171]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.